Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry …

Related Keywords

Boston ,Massachusetts ,United States ,London ,City Of ,United Kingdom ,Germany ,Jonas Dyhrfjeld Johnsen ,University College London Ear Institute ,Trends In Drug Development For Age ,Royal National Institute For Deaf People ,Hearing Research Center Department Of Otolaryngology ,Translational Hearing Research Group ,National Institute For Health ,Human Hearing Development Impacts Preclinical Efficacy ,Care Research ,Acousia Therapeutics ,Acousia Therapeutics Gmbh ,Annual Inner Ear Disorders Therapeutics Summit ,Preclinical Study Design ,Enhancing Probability ,Drug Development ,Age Related Hearing ,Chief Development Officer ,Chosen Animal Model ,Lessons Learned ,Locally Administered ,Therapeutics Summit ,Royal National Institute ,Deaf People ,National Institute ,Hearing Research Center ,Neck Surgery ,Inner Ear Biology Workshop ,Drug Candidate Uniquely Suited ,Therapeutics Gmbh ,Gesundheit ,Wissenschaft ,Rforschung ,Resseaussendung ,Ressemitteilung ,Pa ,Its ,Pa Ots ,